Maziar Mike Doustdar
Maziar Mike Doustdar is a prominent Austrian-Iranian business executive, currently serving as the head of international operations for Novo Nordisk, a leading pharmaceutical company specializing in obesity treatments. Based in Zurich, Doustdar oversees a substantial revenue stream for the company, which has become a market leader in innovative weight-loss injections. His career at Novo Nordisk began at the age of 22, and through years of dedication and various roles, he ascended to his current position, demonstrating a remarkable ability to navigate the complexities of the pharmaceutical industry. Known for his approachable leadership style, Doustdar emphasizes the importance of humility in a rapidly growing business segment.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Switzerland | 1 | 7.00 | 0.08% | +0% | 8,654,622 | 7,025 | $700,000 | 568$ |
| Totals | 1 | 8,654,622 | 7,025 | $700,000 | 568$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Switzerland:
Maziar Mike Doustdar is the CEO of Novo Nordisk and is implementing a major cost-cutting program to address the company's financial challenges.
7
Switzerland:
Maziar Mike Doustdar has taken over the leadership of Novo Nordisk.
5
Switzerland:
Maziar Mike Doustdar has been appointed as the new President and CEO of Novo Nordisk.
7
Italy:
Maziar Mike Doustdar replaced Lars Fruergaard Jørgen as CEO of Novo Nordisk on August 7.
5
United Kingdom:
Maziar Mike Doustdar will take over as chief executive on 7 August.
6
Denmark:
Maziar Mike Doustdar has dedicated his entire working life to Novo Nordisk.
9
Sweden:
Maziar Mike Doustdar has been appointed as the new CEO of Novo Nordisk.
7
Denmark:
Maziar Mike Doustdar has been appointed as the new CEO of Novo Nordisk.
9
Switzerland:
Maziar Mike Doustdar is the head of international business for the Danish pharmaceutical group Novo Nordisk.
8